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Photoinduced effects 
of m-tetrahydroxyphenylchlorin loaded 
lipid nanoemulsions on multicellular tumor 
spheroids
Doris Hinger1* , Fabrice Navarro2,3, Andres Käch4, Jean‑Sébastien Thomann2,3, Frédérique Mittler2,3, 
Anne‑Claude Couffin2,3 and Caroline Maake1
Abstract 
Background: Photosensitizers are used in photodynamic therapy (PDT) to destruct tumor cells, however, their 
limited solubility and specificity hampers routine use, which may be overcome by encapsulation. Several promising 
novel nanoparticulate drug carriers including liposomes, polymeric nanoparticles, metallic nanoparticles and lipid 
nanocomposites have been developed. However, many of them contain components that would not meet safety 
standards of regulatory bodies and due to difficulties of the manufacturing processes, reproducibility and scale up 
procedures these drugs may eventually not reach the clinics. Recently, we have designed a novel lipid nanostructured 
carrier, namely Lipidots, consisting of nontoxic and FDA approved ingredients as promising vehicle for the approved 
photosensitizer m‑tetrahydroxyphenylchlorin (mTHPC).
Results: In this study we tested Lipidots of two different sizes (50 and 120 nm) and assessed their photodynamic 
potential in 3‑dimensional multicellular cancer spheroids. Microscopically, the intracellular accumulation kinetics of 
mTHPC were retarded after encapsulation. However, after activation mTHPC entrapped into 50 nm particles destroyed 
cancer spheroids as efficiently as the free drug. Cell death and gene expression studies provide evidence that encap‑
sulation may lead to different cell killing modes in PDT.
Conclusions: Since ATP viability assays showed that the carriers were nontoxic and that encapsulation reduced dark 
toxicity of mTHPC we conclude that our 50 nm photosensitizer carriers may be beneficial for clinical PDT applications.
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Background
A wealth of publications report on the development of 
promising novel nanoparticulate drug carriers includ-
ing liposomes [1], polymeric nanoparticles [2], metallic 
nanoparticles [3] and lipid nanocomposites [4]. However, 
many of them contain components that would not meet 
safety standards of regulatory bodies such as the Euro-
pean Medicines Agency (EMA) or the US food and drug 
administration (FDA) [5]. Furthermore, due to difficulties 
of the manufacturing processes, reproducibility and scale 
up procedures these drugs may eventually not translate 
into the clinics.
Recently, we have designed a novel lipid nanostruc-
tured carrier, namely Lipidots, consisting of nontoxic and 
FDA approved ingredients: wax and soybean oil serve as 
core components and lecithin as membranous hull with 
a polyethylene glycol (PEG) coating [6]. Containing only 
natural compounds, they are likely to be broken down 
and removed or recycled by the body [7]. Lipidots may be 
utilized and adapted for many different applications such 
as fluorescent imaging probes, contrast agent carriers, 
or targeted drug delivery [8]. They offer the possibility 
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to tune the viscosity of their lipid core, thereby adapting 
the release of an encapsulated compound to the desired 
profile [9]. Moreover, Lipidots can be manufactured with 
high colloidal stability at laboratory and industrial scales 
using ultrasonics or high pressure homogenization [6].
An interesting future application of Lipidots may be in 
the context of photodynamic therapy (PDT), a modality 
which is currently receiving increasing clinical attention 
as a promising anti-cancer treatment [10]. PDT princi-
ples rely on the activation of a light-sensitive drug (the 
photosensitizer, PS), which, through oxidative reaction 
cascades of type I and type II leads to the generation 
of cytotoxic reactive oxygen species (ROS) and strictly 
localized cell death. Remarkably, PDT has the potential to 
overcome disadvantages of standard oncologic regimes 
such as surgery, chemo- or radiotherapy because it is 
minimal invasive, bears little risk for the development 
of resistance and lacks severe side effects [11]. However, 
the efficiency of PDT critically depends on a high local 
accumulation of the PS at the tumor site. But since many 
potent PSs are hydrophobic, they tend to aggregate in 
aqueous environments (e.g. after intravenous injection), 
with negative consequences for their biodistribution and 
photoactivity, which can eventually lead to unsatisfactory 
therapeutic effects [12]. With the aim to improve PDT 
applications, various PSs have been entrapped into nano-
carriers, including e.g. Photophrin, hypocrellin A, chlorin 
e6, tetraarylporphyrin, the near infrared dye indocyanine 
green [13] or the powerful FDA approved second genera-
tion PS m-tetrahydroxyphenylchlorin (mTHPC) [14].
In a previous study we have reported on the successful 
and reproducible encapsulation of mTHPC (generic name: 
Temoporfin) into Lipidots and their extensive characteri-
zation [15]. While our physico-chemical and photophysi-
cal data indicate that these particles may be well suited for 
PDT applications, results about their biological activity are 
only very preliminary yet [15]. In the present study we have 
thus set out to investigate PDT effects of mTHPC-loaded 
Lipidots for the first time in an advanced in vitro 3-dimen-
sional (3D) head and neck cancer cell model. To estimate 
their potential for clinical PDT use, we produced Lipidots 
with two sizes (50 and 120 nm) and, after mTHPC encap-
sulation, compared their in  vitro effects to free mTHPC 
in terms of light-induced toxicity, penetration properties, 
dispersion behaviour, PDT effects, cell death mechanisms 
and gene expression patterns.
Methods
Chemicals
MTHPC was obtained from Biolitec, Jena, Germany as 
powder. A stock solution of 1.47 mM (1 mg/mL) in 100 % 
ethanol was prepared and stored at 4  °C in the dark. 
1,1′-dioctadecyl-3,3,3′,3′-tetramethylindodicarbocyanine 
perchlorate (DiD) was purchased from Life Technologies 
(Carlsbad, USA). If not otherwise indicated, chemicals 
were purchased from Sigma-Aldrich, Buchs, Switzerland.
Nanoparticle preparation
Lipidots were prepared according to Delmas et al. [9] and 
Navarro et  al. [15]. Briefly, the manufacturing process 
consists of mixing an aqueous phase and a lipid phase 
which are separately prepared, including on the one hand 
MyrjS40 surfactant dissolved into 1X phosphate buff-
ered saline (PBS) (154  mM NaCl, 0.1  M Na2HPO4, pH 
7.4) and on the other hand soybean oil and wax (Sup-
pocire NB) under melted state. The ultrasonication step 
is performed using a VCX750 ultrasonic processor dur-
ing 20  min (power input 190  W, 3-mm probe diameter, 
Sonics). MTHPC was incorporated into the lipid mix-
ture as a concentrated solution in ethyl acetate and after 
vacuum elimination of organic solvent, the oily phase 
was added to the aqueous phase and emulsification was 
performed as previously described [15]. For 50 nm Lipi-
dots, the dispersion is composed of 37.5 % (w/w) of lipid 
phase (with a lecithin/PEG surfactant weight ratio of 0.19 
and a surfactant/core weight ratio of 1.20) whereas for 
120  nm Lipidots, the dispersion is composed of 43.0  % 
(w/w) of lipid phase (with a lecithin/PEG surfactant 
weight ratio of 0.21 and a surfactant/core weight ratio of 
3.0). The Lipidots were loaded with mTHPC (thereafter 
called M-Lipidots) at two different ratios of numbers of 
PS per nanoparticle for 50 and 120  nm-sized Lipidots, 
respectively (920 and 4600 molecules of mTHPC/par-
ticle, respectively). The mTHPC concentrations were 
determined by high-performance liquid chromatography 
(HPLC) analysis. HPLC of prepared samples was car-
ried out on a Sunfire C18 column (250  mm ×  4.6  mm, 
i.d. 5  µm) at 30  °C. The mTHPC compound was eluted 
at 2.10 min using a isocratic mobile phase of acetonitrile/
H2O trifluoroaceticacid, 0.1 %: 9/1 at 1 mL/min flow rate 
after injection of 30 µL. The UV detection is operated at 
425 nm. The mTHPC concentrations were assessed using 
a calibration curve in the range of 1–12 µg/mL. For com-
parisons at constant PS content, all working solutions 
were diluted using PBS to obtain equivalent mTHPC 
amounts in solution to be added in cell culture media for 
PDT treatment (3.67, 7.34, 14.69  µM mTHPC content). 
For in  vitro additional fluorescence imaging and flow 
cytometry purposes, dye-doped nanoparticles, thereafter 
called D-Lipidots, were prepared as previously described 
[16] by incorporating DiD lipophilic indocyanine into the 
oily core of 50 nm Lipidots.
Monolayer cell culture
CAL-33 tongue squamous cell carcinoma cells (DSMZ, 
Braunschweig, Germany), were grown in RPMI without 
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phenol red, 10 % FCS, 2 mM Glutamax (Life Technolo-
gies), and 1 % Penicillin/Streptomycin (LifeTechnologies). 
Cells were kept in 75 cm2 cell culture flasks at 5 % CO2 
and 37 °C. Cell counting was performed with a Neubauer 
chamber (Laboroptik Ltd., Lancing, UK) on an aliquot of 
cells after staining with 0.1 % (w/v) nigrosin in PBS.
Spheroid cell culture
The bottoms of 96 well plates were coated with 65  µL 
1.5  % (w/v) agarose (Life Technologies) in cell culture 
medium without supplements. 3D cell culture spheroids 
were prepared by putting 96 drops of 5000 CAL-33 cells 
in 10 µL complete cell culture medium on the inner side 
of the lid of a 96 well plate. Then the lids with the hanging 
drops were put back on the plates and incubated for 24 h. 
Thereafter, 190 µL of complete cell culture medium was 
added to the wells and the drops were spun down shortly 
in a centrifuge (Virion, Zürich, Switzerland) and incu-
bated for another 72  h. By that time the spheroids had 
reached an average diameter of 200 µm and were imme-
diately used for the experiments [17].
Light microscopy
Monolayer cells
CAL-33 cells were seeded on 12  mm glass cover slips 
(Karl Hecht, Sondheim, Germany) and incubated with 
7.34  µM mTHPC or M-Lipidots or 1  µM D-Lipidots in 
cell culture medium for up to 28 h in the dark. The cover 
slips were washed twice with PBS and subsequently 
fixed for 20 min with 4 % (w/v) formaldehyde (FA)/PBS. 
After washing they were mounted on microscopic slides 
(Menzel, Braunschweig, Germany) with Glycergel (Dako, 
Glostrup, Denmark) and analyzed with a confocal laser 
scanning microscope (Leica SP5, Heerbrugg, Switzer-
land). MTHPC was excited at 488  nm and fluorescence 
was detected between 590–660  nm. Images were ana-
lyzed with the imaging software Imaris (Bitplane, Belfast, 
UK).
Spheroids
Spheroids were incubated with 7.34  µM of mTHPC or 
M-Lipidots in 100 µL cell culture medium for up to 28 h 
in 96 well plates in the dark. Spheroids were picked with 
a 1 mL pipette and transferred to microcentrifuge tubes. 
After washing twice with PBS spheroids were fixed in 
4  % (w/v) FA/PBS for 1  h, washed in PBS and analyzed 
in 18-well µ-slides (IBIDI) by widefield fluorescence 
microscopy (Leica DMI 6000) or confocal laser scanning 
microscopy (Leica, SP5). Per time point, 3–5 images were 
acquired using differential interference contrast (DIC) 
and epifluorescence and mean fluorescence was calcu-
lated from regions of interest (ROIs) which were drawn 
around the cell assemblies in the DIC channel with Leica 
AS lite software. Confocal laser scanning microscopy 
(Leica SP5) was performed on 3–5 fixed spheroids per 
condition with a 20×  objective (HC Plan APO). After 
spheroid integrity was confirmed by DIC imaging, optical 
sectioning was performed with an argon laser at 488 nm 
for excitation of mTHPC. Pictures from the center of the 
spheroids were taken and processed with the imaging 
software Imaris (Bitplane, Belfast, UK).
Cytotoxicity assessment
Spheroids were incubated with 3.67, 7.34 and 14.69 µM 
of mTHPC or M-Lipidots for 24 h in 96 well plates in the 
dark. Substance-mediated damage (i.e. dark toxicity) was 
assessed by either measuring spheroid areas as ROIs with 
widefield microscopy and the Leica AS imaging software 
or by means of an ATP luciferase viability assay (Pro-
mega, Fitchburg, USA). For the ATP luciferase viability 
assay 100 µL of Cell Viability Assay solution was added to 
each well after drug incubation, the contents were mixed 
by pipetting and the plate was transferred for 20 min to a 
shaker. Subsequently bioluminescence was measured in a 
microplate reader (Biotek, Vermont, USA).
Phototoxicity assessment
Spheroids were incubated with 3.67, 7.34 and 14.69 µM 
of mTHPC or M-Lipidots for 24 h in 96 well plates in the 
dark. Subsequently the plates were subjected to PDT by 
illuminating with white light from 2.5 cm above (3440 lx; 
fluorescent tube SYLVA-NIA standard F15 W/154, day-
light) for 20  min. To ensure an even illumination, the 
outer rim of the well plates was never used for experi-
mentation and the sequence of samples within the plate 
was changed between repetitions. Spheroid areas were 
microscopically determined as described above and cell 
survival was determined by ATP luciferase viability assay 
5 h after irradiation as described above.
Apoptosis assay
Spheroids were incubated with 7.34  µM mTHPC or 
M-Lipidots for 24  h. After illuminating for 1  min (con-
ditions as described above) spheroids were incubated 
for another 1.5 h with 100 µL 15 µM Hoechst 33342 and 
30× Flica reagent (FAM Flica Poly Caspase kit, Immu-
noChemistry Technologies, Enzo Life Sciences, Lausen, 
Switzerland). The spheroids were subsequently harvested 
with a 1  mL pipette and transferred to microcentrifuge 
tubes. After washing twice with wash buffer (FAM Flica 
Poly Caspase Kit) they were fixed for 1 h in fixing solu-
tion (FAM Flica Poly Caspase Kit) and analyzed in 18 well 
µ-slides (IBIDI) with a confocal laser scanning micro-
scope (Leica SP5, Heerbrugg, Switzerland) within 24 h.
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Electron microscopy
Spheroids were incubated for 24  h with 3.67 µM 
mTHPC or 50  nm  M-Lipidots and irradiated for 1  min 
as described above. One hour after light treatment they 
were washed and fixed and sequentially treated with 
OsO4 and uranylacetate. After dehydration they were 
embedded in Epon/Araldite and sections were contrasted 
with uranyl acetate and lead citrate. They were examined 
with a CM100 transmission electron microscope (FEI, 
Eindhoven, The Netherlands) or with an Auriga 40 scan-
ning electron microscope (Zeiss, Oberkochen, Germany). 
For a more detailed description see Additional file 1.
Quantitative reverse transcription polymerase chain 
reaction (qRT‑PCR)
A total of 120 spheroids were incubated with 3.67  µM 
mTHPC or 50 nm M-Lipidots for 24 h. After illuminat-
ing for 1 min as described spheroids were incubated for 
another 2 h, subsequently harvested with a 1 mL pipette 
and transferred to microcentrifuge tubes. They were 
washed twice with PBS and resuspended in 600 µL lysis 
buffer (Qiagen, Venlo, The Netherlands), vortexed vigor-
ously and passed 30 times through a 1 mL syringe with 
a 20 gauge needle. Total RNA was extracted with the 
RNeasy Micro Kit (Qiagen) as described per manufac-
turer’s instructions, processed with a cNDA synthesis kit 
(Qiagen) and the obtained cDNA used for a quantitative 
PCR array (Human Cancer Drug Targets RT2 Profiler 
PCR Array, Qiagen). For further details please refer to the 
Additional file 1.
Flow cytometry
Flow cytometry analysis of the interaction of fluorescent 
D-Lipidots with cells was performed using a 9 colors 
FACS BD LSR2 equipped with lasers emitting at 488 and 
633  nm (BD, Franklin Lakes, USA). CAL-33 cells were 
seeded at a density of 105 cells per well in 12 well plates 
and incubated for 24  h. D-Lipidots with a diameter of 
50  nm were incubated at the corresponding concentra-
tion of 1 µM DiD in presence of cell monolayers for 2, 3 
or 6 h in complete cell culture medium. Thereafter, cells 
were rinsed with PBS (×2), harvested by the addition of 
trypsin followed by a centrifugation, and then fixed with 
2 % FA before flow cytometry analysis. 10,000 to 20,000 
events were recorded. The data from fluorescence meas-
urements at an emission wavelength of 660 nm for DiD 
were analyzed using DIVA v8.1 software (BD) by using 
the overlay option.
Statistical evaluation and graphical modelling
Two-way ANOVA of cell toxicity and phototoxic-
ity data was analyzed from at least two independent 
experiments and five replicates per condition. Means 
are plotted ±  standard deviations. Statistics and graphi-
cal plots were established and analyzed with GraphPad 
Prism software (Graphpad Software, La Jolla, USA).
Results
Nanoparticle preparation
To investigate the effect of particle size and PS payload 
on transport and delivery, two series of nanoparticles 
were prepared with two different payloads. For the 50 nm 
nanoparticles, mTHPC was incorporated with a content 
of 920  molecules/particle whereas for 120  nm particles, 
the amount of mTHPC was estimated at 4600 molecules/
particle. Therefore one 120  nm nanoparticle contains 
fivefold more molecules of mTHPC than one 50  nm 
nanoparticle. Expressed in equivalent mTHPC concen-
tration (3.67, 7.34 and 14.69 µM) the solution of 50 nm 
nanoparticles contains fivefold more particles than the 
solution of 120 nm particles. As observed in our prelimi-
nary study [15], mTHPC was efficiently encapsulated into 
lipid nanoparticles without affecting neither the colloidal 
properties of the carrier nor photophysical properties of 
the loaded PS. Indeed, an aggregation of mTHPC inside 
the lipid core of nanoparticles can be observed only for 
50 nm particle at high payload (>4 %w/w total lipid, data 
not published). Estimated from the whole excipients ini-
tially incorporated in the Lipidot formulation, mTHPC 
was loaded in our study at 2.8 and 1.0 % w/w for 50 and 
120 nm particles, respectively (Table 1).
Particle size and size distribution of lipid nanoparticles
Dynamic light scattering (DLS) technique was used to 
determine the particle hydrodynamic diameter (in nm), 
particle size distribution (expressed by polydispersity 
index PDI) using Zetasizer Nano ZS (Malvern Instru-
ments, France). At least three different nanoparticle 
batches (lipid dispersed phase weight fraction: 10  %) 
are measured per condition. Data were expressed as 
mean ±  standard deviation of three independent meas-
urements performed at 25 °C (Table 1).
Lipidot size drives uptake kinetics in CAL‑33 cells
Using confocal laser scanning microscopy and CAL-
33 monolayers and spheroids, uptake of 50  and 
120 nm M-Lipidots was investigated over time and com-
pared to free mTHPC (Fig.  1). In CAL-33 monolayer 
cultures, fluorescence of free mTHPC could be read-
ily detected after 2  h of incubation as a diffuse signal 
throughout the cytoplasm, sparing the nucleus. In con-
trast, no fluorescence from our nanoparticle formula-
tions was apparent at this time point. Only after 6 h both 
sizes of M-Lipidots were visible with the same distribu-
tion pattern as free mTHPC, however, the fluorescence 
was markedly weaker with 120 nm M-Lipidots compared 
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to 50 nm M-Lipidots. The intracellular distribution pat-
tern stayed similar until 28  h but fluorescence accumu-
lated over time for all formulations (Fig. 1a–c).
To obtain further information with regard to uptake 
kinetics, flow cytometry was used to measure in CAL-33 
the fluorescence of 50 nm D-Lipidots over time (Fig. 2). 
These 50  nm D-Lipidots show the same accumulation 
behavior as 50  nm  M-Lipidots (Fig.  2a), but are better 
suited for flow cytometry applications. Data confirmed 
microscopic observations in CAL-33 cells, showing an 
increase of fluorescence intensity after 6 h of incubation 
as compared to earlier time points (Fig. 2b).
To better predict the in vivo behavior, uptake was then 
investigated in CAL-33 spheroids (Fig. 1d–f). In this 3D 
model of an avascular mini tumor, free mTHPC accumu-
lated in the outer cell layer at about the same time as in 
monolayer cells (2 h), however, it took up to 6 h until the 
PS was penetrating further into the spheroid. Eventually 
it reached the spheroid core at 24 h with a modest overall 
fluorescence increase until 28 h. At these late time points, 
fluorescence signals showed a homogeneous distribution 
within the spheroid. The weaker fluorescent signals of 
50 nm M-Lipidots were apparent in the outer cell layers 
after 4 h, and continued to penetrate slowly deeper into 
Table 1 Physicochemical characterization of Lipidots
Data with standard deviation
a Expressed w/w of total lipids (included in nanoparticle formulation)
b Empty Lipidots
Lipid (mg/mL) Numberof parti‑
cles/mL
MTHPC mol‑
ecules/particle
mTHPC (µg/mL) Drug loadinga Hydrodynamic 
diameter (nm)
Poly‑dispersity 
index
50 nm M‑Lipidot 50 7.27565 × 1014 ~920 722 2.8 % 47.7 ± 1.1 0.153 ± 0.01
120 nm M‑Lipidot 50 5.26306 × 1013 ~4600 262 1.0 % 111.2 ± 2.2 0.103 ± 0.01
50 nm Lipidotb 50 7.27565 × 1014 – – – 49.5 ± 1.5 0.170 ± 0.07
120 nm Lipidotb 50 5.26306 × 1013 – – – 95.4 ± 3.4 0.120 ± 0.05
Fig. 1 Confocal laser scanning microscopy images of CAL‑33 cells incubated for 28 h with free mTHPC (a, d), 50 nm M‑Lipidots (b, e) and 
120 nm M‑Lipidots (c, f) in monolayers (a–c) and spheroids (d–f). Concentration for all treatments: 7.34 µM mTHPC. Scale bar 50 µm
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the spheroid center. At 28 h the core was fluorescent, but 
the signal displayed a more punctuate and less homoge-
neous pattern. Compared to 50 nm M-Lipidots, penetra-
tion of 120 nm M-Lipidots was retarded, most of which 
did not reach the center even at 28 h as evidenced by a 
less fluorescent spheroid core.
Semiquantitative analyses of microscopy data con-
firmed that time dependent uptake curves were dif-
ferent between free mTHPC and M-Lipidots in the 
spheroid model (Fig.  3). Free mTHPC was taken up in 
a nonlinear, asymptotical way with high initial uptake 
rates and quickly decreasing rates over time whereas 
120 nm M-Lipidots were taken up by the spheroid in an 
almost linear fashion during the whole time of the exper-
iment at a very low initial uptake rate. The uptake curve 
of the 50 nm M-Lipidots presents an uptake in a nonlin-
ear way but at a lower initial uptake rate as free mTHPC. 
Based on uptake studies, further studies were therefore 
performed after a 24 h exposure to the compounds.
The nanoformulations are less cytotoxic than the free 
substance at high drug concentrations
To obtain information about a possible cytotoxicity 
of our nanocarriers, we first tested empty Lipidots by 
means of an ATP luciferase viability assay that measures 
cell viability in CAL-33 spheroids (Fig.  4a). A compari-
son revealed that both 50 and 120 nm Lipidots are well 
tolerated for concentrations of particles correspond-
ing to the equivalent mTHPC concentration from 0 to 
14.69  µM (≙69.3–692.9  µg/mL lipid [50  nm]; 190.7  µg/
mL–1.90 mg/mL lipid [120 nm]), with the smaller parti-
cles being slightly superior (p  <  0.01). While the 50  nm 
particles did not exhibit any toxicity at the tested concen-
trations the 120  nm particles reduced viability by 10  %. 
As a next step, cytotoxic effects of PS-loaded M-Lipidots 
were compared to free mTHPC in CAL-33 spheroids 
(Fig.  4b). While free mTHPC showed a clear toxicity 
(68  % viability) in the dark at the highest concentration 
tested (14.69 µM), encapsulation of mTHPC into Lipidots 
resulted in a significantly reduced dark toxic effect (78 % 
viability with the 50 nm Lipidots; 86 % viability with the 
120 nm Lipidots, p < 0.001).
The 50 nm M‑Lipidots show high photodynamic potency 
similar to free mTHPC
The PDT effects mediated by M-Lipidots or free mTHPC 
were investigated in CAL-33 spheroids (Figs.  5, 6). Our 
microscopic analyses showed that PDT with both free 
mTHPC and 50  nm  M-Lipidots induced a pronounced 
and comparable destruction of the spheroids (Fig.  5). 
Although the size reduction was difficult to microscopi-
cally measure under conditions of high destruction, the 
results correlated with the respective ATP luciferase 
viability assays (Fig.  6b). The 50  nm Lipidots as well as 
free mTHPC reduced spheroid sizes by 100 % at higher 
concentrations (p  <  0.001). However, after PDT with 
120  nm  M-Lipidots, even at the highest concentration 
(14.69 µM), only mild phototoxic effects were visible with 
size reductions by only 34 % (Figs. 5, 6a, p < 0.001). These 
limited PDT effects of 120 nm M-Lipidots could also be 
confirmed by ATP luciferase viability assays (Fig.  6b). 
Viability after PDT with the highest concentration 
(14.69 µM) was 1.8 % with mTHPC, 6.6 % with the 50 nm 
particles and 66.2 % with the 120 nm particles (p < 0.001). 
Free mTHPC causes apoptosis and necrosis 
while 50 nm M‑Lipidots cause mostly apoptosis
By “FLICA” apoptosis assays high pan-caspase activ-
ity was detected in CAL-33 spheroids after PDT with 
50 nm M-Lipidots (Fig. 7c) and, to a lesser extent, after 
Fig. 2 a Confocal laser scanning microscopy image of CAL‑33 cells incubated with 1 µM D‑Lipidots (50 nm) for 6 h. Scale bar 20 µm. b Flow cytom‑
etry analyses of CAL‑33 cells incubated with 1 µM D‑Lipidots (50 nm) for 2 h (pink), 3 h (light brown), 6 h (red), as compared to control (grey)
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treatment with free mTHPC and irradiation (Fig.  7b). 
Very low caspase staining occurred after PDT with 
120  nm  M-Lipidots (Fig.  7d) which was barely more 
intense than staining of control spheroids (Fig. 7a).
An investigation of CAL-33 spheroids at the ultra-
structural level with electron microscopy confirmed 
different modes of cell death as observed after PDT 
with mTHPC or 50  nm  M-Lipidots (Fig.  8). Untreated 
controls showed intact spheroid structures and most 
cells displayed well preserved cell organelles (Fig.  8a, 
d). MTHPC-induced PDT seemed to disrupt spheroid 
structure as a whole, causing cells to die either in an 
apoptotic or in a necrotic manner (Fig. 8b, e). Apoptosis 
was recognizable by the condensed chromatin structure 
and well preserved cell membranes of some dying cells. 
However, necrotic features like destroyed cell organelles 
and membranous cellular debris were present as well. 
Inside several cells inclusion bodies with grainy depos-
its were visible that may be aggregated and contrasted 
mTHPC (Fig. 8g). PDT with 50 nm M-Lipidots was pri-
marily damaging the spheroid center leaving an outer 
rim of cells intact under these conditions (Fig. 8c). In the 
spheroid center cells were primarily showing features of 
apoptotic cell death, as described above (Fig. 8f ). Addi-
tionally, in the outer cell layer, close to the cytoplasmic 
membrane, vesicles with enclosed sphere-like structures 
of about 50 nm were present that may represent M-Lipi-
dots (Fig. 8h).
Lipidot‑PDT affects similar pathways as mTHPC‑PDT
To further explore possible differences between mTHPC- 
and 50  nm  M-Lipidot-mediated PDT, we analyzed the 
expression of 84 known cancer drug target genes by 
means of qRT-PCR (Fig. 9). Compared to the untreated 
control, no gross differences in overall expression pat-
terns could be discovered after PDT, since the same 33 
genes were upregulated after both regimes. However, 
the upregulation was generally stronger after mTHPC-
PDT. This was e.g. obvious for the expression of PTGS2, 
TXNRD1, AKT1, NFKB1, EGFR, PIK3C3, NRAS, PLK2, 
PLK3, RHOB, and HSP90AA1, where a more than two-
fold higher upregulation was found after mTHPC-PDT 
compared to M-Lipidot-PDT. However, it should be 
noted that the same pathways were affected in the same 
direction (only upregulation, no downregulation) after 
both PDT regimes. Among others, we detected signs 
for abnormal regulation of KRAS and NRAS and an 
increase of transcription factors ATF2, HIF1A, NFKB1, 
TP53 despite of the upregulation of histone deacety-
lases HDAC1, HDAC2 and HDAC4. Genes that were not 
expressed and/or unaltered after both PDT regimes are 
summarized in Additional file 1: Table S1.
Discussion
The powerful PS mTHPC is approved in several European 
countries for palliative PDT of patients with advanced 
head and neck cancer. However, mTHPC formulations 
that e.g. improve solubility of this highly hydrophobic 
drug, reduce its dark toxicity, enhance its intratumoral 
accumulation and/or increase PDT efficacy would be 
beneficial for systemic clinical applications [18].
Fig. 3 Time dependent uptake curves of free mTHPC (a), 
50 nm M‑Lipidots (b) and 120 nm M‑Lipidots (c) established by wide‑
field fluorescence measurement in CAL‑33 spheroids. RFU relative 
fluorescence units. Concentration for all treatments: 7.34 µM mTHPC
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Fig. 4 Cell viability ATP assays of CAL‑33 spheroids after 24 h incubation. a Cytotoxic effects (dark toxicity) of empty Lipidots with an equalized 
amount of lipid content as in b. b Cytotoxic effects (dark toxicity) of 3.67 µM (1), 7.34 µM (2) and 14.69 µM (3) mTHPC or 50/120 nm M‑Lipidots. 
**p < 0.01. ***p < 0.001
Fig. 5 Light microscopy of CAL‑33 spheroids incubated for 24 h with 3.67, 7.34 and 14.69 µM mTHPC or 50/120 nm M‑Lipidots after light irradiation 
with 3440 lx for 20 min
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Fig. 6 a Light microscopic measurements of spheroid areas of CAL‑33 spheroids incubated with 3.67 µM (1), 7.34 µM (2) and 14.69 µM (3) mTHPC 
or 50/120 nm M‑Lipidots with (+) and without (−) light irradiation with 3440 lx for 20 min. b Cell viability ATP assays of CAL‑33 spheroids incubated 
at the same conditions as in a. *p < 0.05. ***p < 0.001
Fig. 7 Confocal laser scanning microscopy images of the fluorescent labeled inhibitor of caspases (FLICA) apoptosis assay after irradiation of CAL‑
33 spheroids with 3440 lx for 1 min. FLICA: green, Hoechst 33342 nuclear stain: blue, mTHPC (red). Untreated control (a) and incubations with mTHPC 
(b), 50 nm M‑Lipidots (c) or 120 nm M‑Lipidots (d). Concentration for all treatments: 3.67 µM mTHPC. Incubation time 24 h. Scale bar 50 µm
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Recently, we introduced solid lipid nanoparticles as 
stable, easy to produce and efficient carriers for mTHPC 
[15]. However, while physico-chemical and photophysi-
cal evaluations indicated their excellent suitability for 
PDT, only scarce information is available yet with regard 
to their behavior in biological systems. In the present 
study we have therefore chosen an advanced in vitro can-
cer spheroid model to investigate for the first time PDT 
effects of these particles (called M-Lipidots) at the cellu-
lar level and compare it to effects of free mTHPC. Cancer 
spheroids are multicellular 3D grown minitumors that 
display features which better mimic the biology of solid 
tumors than standard monolayer cultures, among oth-
ers in terms of intercellular contacts, matrix deposition, 
physiological barriers, cellular inhomogeneity or prolif-
eration properties [19]. Also with regard to ROS diffusion 
and PS penetration a 3D environment may be advanta-
geous. Spheroids have thus been proposed not only as 
superior predictive platforms for testing of drugs but also 
of drug delivery systems [20].
Since diameters of Lipidots can be reliably adjusted 
between 30 and 120  nm by varying wax, oil and sur-
factant content [15], we have here included two exem-
plary sizes of mTHPC-Lipidots, namely 50 and 120 nm. 
In both, monolayer cultures (that served as a reference) 
and spheroids, we found that free mTHPC was taken up 
in a shorter time frame compared to mTHPC encapsu-
lated into Lipidots. The quicker and higher accumulation 
of free mTHPC may be explained by the fact that lipo-
philic PSs can bind to serum proteins and uptake can be 
mediated by low lipid density protein receptors, which is 
considered an efficient mechanism [18]. For in vivo appli-
cations this slower accumulation of M-Lipidots must of 
course be considered but may be outweighed by advan-
tages of Lipidot’s PEG chains that offer a stealth mecha-
nism to avoid fast recognition by the immune system 
[21].
Our experiments further indicated favored uptake 
and superior spheroid penetration properties of the 
50  nm  M-Lipidots over the 120  nm  M-Lipidots. These 
results are in accordance with most literature reports for 
other nanocomposites which suggest a size dependency 
of the uptake behavior and smaller diameters being more 
readily internalized by cells in monolayers [22]. There are 
fewer studies investigating size dependent penetration 
of nanoparticles into spheroids, however, in a work with 
gold nanocomposites the authors also reported a supe-
rior uptake of smaller 50 nm particles over larger 100 nm 
Fig. 8 Transmission electron microscopy images of CAL‑33 spheroids. Untreated control (a, d) and incubations with mTHPC (b, e, g) or 
50 nm M‑Lipidots (c, f, h). Arrows (g) vesicles with precipitate. Arrows (h) engulfed Lipidots. Concentration 3.67 µM mTHPC. Incubation time 24 h. 
Irradiation 1 min at 3440 lx. Scale bar (a–c) 50 µm. Scale bar (d–h) 2.5 µm
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Fig. 9 Fold expression change in spheroids after 24 h incubation with 3.67 µM mTHPC or 50 nm M‑Lipidots and light illumination from 2.5 cm 
above with white light for 1 min at 3440 lx. Gene expression data was normalized against an untreated control and the RPLP0 house keeping gene. 
CFTR/MRP ATP‑Binding Cassette, Sub‑Family C, ABCC1 Member 1, PTGS2 Prostaglandin‑Endoperoxide Synthase 2, TXNRD1 Thioredoxin Reductase 1, 
AKT1 V‑Akt Murine Thymoma Viral Oncogene Homolog 1, AKT2 V‑Akt Murine Thymoma Viral Oncogene Homolog 2, ATF2 Activating Transcription 
Factor 2, HIF1A Hypoxia Inducible Factor 1, Alpha Subunit, NFKB1 Nuclear Factor Of Kappa Light Polypeptide Gene Enhancer In B‑Cells 1, TP53 Tumor 
Protein P53, BCL2 B Cell CLL/Lymphoma 2, CDK7 Cyclin‑Dependent Kinase 7, CDK9 Cyclin‑Dependent Kinase 9, MDM2 MDM2 Proto‑Oncogene, E3, 
EGFR Epidermal Growth Factor Receptor, ERBB2 Erb‑B2 Receptor Tyrosine Kinase 2, ERBB3 Erb‑B2 Receptor Tyrosine Kinase 3, HDAC1 Histone Dea‑
cetylase 1, HDAC2 Histone Deacetylase 2, HDAC4 Histone Deacetylase 4, PIK3C2A Phosphatidylinositol‑4‑Phosphate 3‑Kinase, Catalytic Subunit Type 
2 Alpha, PIK3C3 Phosphatidylinositol 3‑Kinase, Catalytic Subunit Type 3, PIK3CA Phosphatidylinositol‑4,5‑Bisphosphate 3‑Kinase, Catalytic Subunit 
Alpha, KRAS Kirsten Rat Sarcoma Viral Oncogene Homolog, V-Ras Neuroblastoma RAS Viral, NRAS Oncogene Homolog, PLK2 Polo‑Like Kinase 2, PLK3 
Polo‑Like Kinase 3, PRKCD Protein Kinase C, Delta, PRKCE Protein Kinase C, Epsilon, RHOB Ras Homolog Family Member B, TOP2B Topoisomerase 
(DNA) II Beta 180 kDa, CTSB Cathepsin B, TNKS Tankyrase, and Heat Shock Protein 90 kDa Alpha (Cytosolic), Class A Member 1 (HSP90AA1)
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ones [23]. However, we cannot exclude that the stronger 
fluorescence signal observed after incubation with 
50 nm M-Lipidots may also be due to the fact that five-
fold more particles were present in the working solution 
of 50  nm  M-Lipidots compared to 120  nm  M-Lipidots. 
This is related to manufacturing processes and the aim 
to reach equivalent mTHPC concentrations with both 
M-Lipidot sizes. Furthermore, fluorescence with the nan-
oparticles was markedly weaker when compared to free 
mTHPC which is why we cannot exclude that quenching 
effects occur in the presence of cells.
For the following PDT experiments, we used a white 
light source rather than a laser to activate the PS. In a 
previous study we have shown that this is perfectly fea-
sible and may be advantageous to detect (subtle) differ-
ences between effects of treatment regimes [24]. With the 
aim to preserve some morphology and avoid complete 
RNA degradation [25, 26] for our microscopic and RNA 
studies, we furthermore had to reduce the illumination 
time from 20 to 1 min. We observed a strong and compa-
rable light-induced destruction of spheroids exposed to 
free mTHPC or 50 nm M-Lipidots. This similar PDT effi-
ciency was despite our observation of a slightly different 
microscopic fluorescence distribution pattern within the 
spheroid of free mTHPC and M-Lipidots, respectively. 
The observed PDT effects complemented our previous 
study, where we have shown in a cell-free environment 
that 30, 50 and 100  nm mTHPC-Lipidots are capable 
of producing high quantum yields after illumination 
and that singlet oxygen may diffuse through the Lipi-
dot shell to the surrounding [15]. As predicted because 
of their observed delayed and weaker cellular uptake, 
120 nm M-Lipidots caused almost no PDT effects under 
the applied mild activation conditions. While effects may 
be improved with stronger illumination regimes, we have 
shown previously that ROS diffusion from larger Lipidots 
is anyway worse than from smaller ones [15].
From EM studies and the apoptosis assay, it was evi-
dent that spheroid centers were more damaged after PDT 
with the 50 nm Lipidots, although fluorescence accumu-
lation was highest at the spheroid periphery. We propose 
that a decreasing nutrient gradient towards the spheroid 
center may render those cells more susceptible to PDT, 
and therefore also low PS doses will be sufficient to kill 
them.
Although PDT with both the free PS as well as the 
50 nm M-Lipidots efficiently destroyed spheroids, under-
lying mechanisms turned out to feature differences under 
our experimental conditions, i.e. necrosis and apoptosis 
with mTHPC-PDT, and apoptosis with 50  nm  M-Lipi-
dot-PDT. The reasons for that are not clear yet. While 
it is well known that the subcellular localization of a PS 
governs PDT cell death pathways [27], we found similar 
cytoplasmic fluorescence patterns of mTHPC with both 
formulations. However, necrotic mechanisms have been 
reported to occur with stronger cellular photodamage 
[27]. Since light doses were the same, it may therefore 
be speculated that under the same conditions treatment 
with M-Lipidots initiated slightly milder PDT effects 
than free mTHPC. Whether this is a consequence of 
quantitative PS uptake, exact intracellular distribution or 
the nanocarrier has to be investigated.
Stronger photodamage after PDT with free mTHPC 
may also be concluded from our RNA expression stud-
ies where we detected always a more pronounced 
gene regulation. For several genes a more than two-
fold higher upregulation was found after mTHPC-PDT 
compared to M-Lipidot-PDT. As the same pathways 
were affected in the same direction (only upregulation, 
no downregulation) after both PDT regimes, it indi-
cates common mechanisms of free and Lipidot-encap-
sulated mTHPC. The changed expression patterns 
reflect the cell’s complex acute responses to (oxidative) 
stress due to our PDT regimes. Many of the upregu-
lated genes may have dual roles for apoptosis or anti-
apoptosis and it is not clear yet whether we observe the 
cell’s efforts to initiate rescue mechanisms or the begin-
ning of cell death. Apparently, many different pathways 
are dysregulated in parallel. Among others, we detected 
signs for abnormal regulation of the RAS signalling 
pathway, chromatin remodeling or an increase of tran-
scription factor RNA despite of the upregulation of his-
tone deacetylases.
In accordance with our previous studies with 30, 50 and 
100 nm particles in MCF-7 monolayer cultures [14] the 
biocompatibility of empty 50 and 120 nm Lipidots could 
be here confirmed for CAL-33 spheroids. The observed 
slightly higher cytotoxicity of 120  nm Lipidots may be 
caused by their increased lipid concentration compared 
to 50 nm Lipidots, as observed before [14]. However, this 
difference may not be biologically relevant, leaving more 
than 90 % of cells vital.
Dark toxicity of PSs is an important issue for clinical 
PDT applications that may cause detrimental effects on 
healthy cells. This also applies to the strong PS mTHPC 
for which cytotoxic effects without light activation are 
well known. In our spheroid model we could demon-
strate that the encapsulation of mTHPC into Lipidots 
significantly reduced unwanted dark toxicity of this PS 
at high concentrations. However, we cannot exclude 
that the lower toxicity is at least partially due to a lower 
uptake of mTHPC into the cells. Still, considering the 
outstanding biocompatibility of our carrier it may allow 
for systemic applications of higher doses of mTHPC for 
improved PDT without the risk for light-independent 
effects in patients.
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Various different approaches have been proposed 
in the past, including the development of e.g. lipo-
somal mTHPC formulations [28, 29] or the encap-
sulation of mTHPC into nanoparticles composed of 
poly(lactic-co-glycolic acid) [30], poly(lactic-co-glycolic 
acid)-b-poly(ethylene glycol) [31], poly(ethylene gly-
col) methacrylate-co-2-(diisopropylamino)ethyl meth-
acrylate copolymers [32], human serum albumin [33], 
organic-modified silica [34] or calcium phosphate. [35] 
These studies describe promising carriers for mTHPC by 
improving solubility and reducing dark toxicity however 
it is not possible to directly compare them as very differ-
ent model systems were used in each case. Furthermore, 
nanotoxicology will be very different depending on the 
materials used in the formulation and can differ greatly 
between in vitro and in vivo studies.
The 50 nm Lipidots display several favorable character-
istics with regard to in vivo applications. Concerning size 
Tang et  al. [36] e.g. could show in  vivo that tumor per-
meation and retention of 50 nm silica particles (the EPR 
effect) was superior to smaller 20  nm ones and larger 
200 nm ones. Furthermore, in two of our former in vivo 
studies with Lipidots as carrier for indocyanine green we 
could report on high chemical stability of the particles of 
over 6  months and a prolonged tumor labelling of over 
1 day [7, 37]. Additionally, Lipidots displayed good long-
term plasma stability and tolerability with low hemolytic 
activity [7, 37].
Conclusions
In conclusion, in an advanced 3D cell culture model, 
50  nm Lipidots have presented themselves as nontoxic 
nanocarriers for hydrophobic photosensitizers such as 
mTHPC that preserve its functionality in PDT. Lipidots 
are not only fully biocompatible and easy to produce, 
but may solve two important problems of mTHPC that 
currently prevent a more widespread clinical use of this 
efficient PS by rendering it water soluble and reducing 
its dark toxicity. The slightly milder PDT effects with 
M-Lipidots may be beneficial in certain clinical settings, 
e.g. where an apoptotic cell death (without inflammation) 
is clinically preferred, such as for tumor ablation.
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